On Tuesday, PepsiCo, Inc. (NYSE:PEP)’s shares declined -0.02% to $95.60.
Cheetos is one of the billion-dollar brands that makes up Frito-Lay North America, the $14 billion convenient foods business unit of PepsiCo (PEP).
Chester Cheetah’s boss is heading out of town for the season and while the boss is away, the Cheetah will play. Everyone’s favorite spokes-cheetah has “borrowed” keys to the boss’ fabulous beach house and has hidden them in two specially marked bags of Cheetos Mix-Ups Flamin’ Hot & Cheezy, Cheetos Flamin’ Hot Crunchy, Cheetos Puffs or Cheetos Crunchy for two lucky families to find. Once a key is found, all the finder needs to do is follow the enclosed instructions to return the key to the Cheetos brand, one of the flagship brands from PepsiCo’s Frito-Lay division. With the winning keys, doors to the beach house will be unlocked so each lucky finder can start their own flamin’ hot vacation for five nights and six flamin’ hot days in either San Diego, Calif.; Laguna Beach, Calif. or Destin, Fla.
The Cheetos Flamin’ Hot Summer sweepstakes marks the introduction of the latest flavor in Frito-Lay’s Cheetos line: Cheetos Mix-Ups Flamin’ Hot & Cheezy. It joins Cheetos Flamin’ Hot Crunchy and the original, Cheetos Crunchy snacks, Cheetos Puffs, and more, all of which promise to make this season extra hot and spicy.
PepsiCo, Inc. operates as a food and beverage company worldwide. Its Frito-Lay North America segment offers Lay’s potato chips, Doritos tortilla chips, Cheetos cheese-flavored snacks, Tostitos tortilla chips, branded dips, Ruffles potato chips, Fritos corn chips, and Santitas tortilla chips.
Ally Financial Inc (NYSE:ALLY)’s shares dropped -0.34% to $23.58.
Ally Financial Inc (ALLY) has planned the release of its second quarter 2015 financial results for Tuesday, July 28, 2015. The press release will be issued at 7:30 a.m. EDT via PR Newswire and on the Ally Media Center website (http://media.ally.com).
Ally Financial Inc. provides financial products and services primarily to automotive dealers and their customers in the United States. It offers dealer financial services, counting a range of financial services and insurance products to automotive dealers and retail customers.
At the end of Tuesday’s trade, Monsanto Company (NYSE:MON)‘s shares dipped -1.34% to $112.81.
Monsanto Company (MON) offered to buy Syngenta AG for $45 billion, the U.S. maker of seeds and weedkillers is exploring other options should the Swiss company continue to reject the deal.
Begemann’s comments are the latest salvo in an escalating war of words between Monsanto and Syngenta as the U.S. seed maker tries to bring its Swiss rival back to the negotiating table. Syngenta Chairman Michel Demare said Tuesday that Monsanto’s bid was simplistic and is unlikely to be approved by regulators.
Monsanto makes Roundup weedkiller and crops that are genetically modified to tolerate the herbicide. It wants to own more proprietary chemicals that can be developed in tandem with new engineered seeds to maximize their value and get them to market faster, Begemann said. Basel-based Syngenta is the world’s largest maker of herbicides, insecticides and other chemicals used to control crop pests. Bayer is the second-biggest.
Monsanto Company, together with its auxiliaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment produces row crop seeds, counting corn, soybean, cotton, and canola seeds principally under the DEKALB, Channel, Asgrow, and Deltapine brands; and vegetable seeds comprising of tomato, pepper, melon, cucumber, pumpkin, squash, beans, broccoli, onions, lettuce, and other seeds under the Seminis and De Ruiter brands.
Eli Lilly and Co (NYSE:LLY), ended its Tuesday’s trading session with -0.30% loss, and closed at $82.67.
Eli Lilly and Co (LLY) has published results of the Phase III REACH trial that evaluated CYRAMZA® (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial’s primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. However, encouraging single-agent CYRAMZA activity was observed, with meaningful improvements in key secondary endpoints in addition to within certain patient subgroups.
The global, randomized, double-blind REACH trial contrast ramucirumab plus best supportive care to placebo plus best supportive care as a second-line treatment in patients with HCC after being treated with sorafenib in the first-line setting. Median overall survival (OS) was 9.2 months on the ramucirumab arm contrast to 7.6 months on the placebo arm (HR 0.866; 95% CI: 0.717-1.046; p=0.1391). While the median OS was not statistically significant, a prespecified subgroup of patients with an elevated baseline of alpha-fetoprotein (AFP) ≥400 ng/mL showed a greater survival improvement with ramucirumab treatment. Median OS in this subgroup of patients was 7.8 months in the ramucirumab arm contrast to 4.2 months in the placebo arm (HR 0.674; 95% CI 0.508-0.895; p=0.0059).
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
